Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 5:7:85.
doi: 10.3389/fcvm.2020.00085. eCollection 2020.

COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2

Alexander Carpenter  1 , Owen J Chambers  2 , Aziza El Harchi  1 , Richard Bond  3 , Oliver Hanington  1 , Stephen C Harmer  1 , Jules C Hancox  1 , Andrew F James  1
Affiliations
Review

COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2

Alexander Carpenter et al. Front Cardiovasc Med. .

Abstract

The COVID-19 pandemic is an unprecedented challenge and will require novel therapeutic strategies. Affected patients are likely to be at risk of arrhythmia due to underlying comorbidities, polypharmacy and the disease process. Importantly, a number of the medications likely to receive significant use can themselves, particularly in combination, be pro-arrhythmic. Drug-induced prolongation of the QT interval is primarily caused by inhibition of the hERG potassium channel either directly and/or by impaired channel trafficking. Concurrent use of multiple hERG-blocking drugs may have a synergistic rather than additive effect which, in addition to any pre-existing polypharmacy, critical illness or electrolyte imbalance, may significantly increase the risk of arrhythmia and Torsades de Pointes. Knowledge of these risks will allow informed decisions regarding appropriate therapeutics and monitoring to keep our patients safe.

Keywords: COVID-19; QT; QTc; arrhythmia; drug safety; hERG.

PubMed Disclaimer

References

    1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020). 10.1101/2020.02.06.20020974. [Epub ahead of print]. - DOI - PMC - PubMed
    1. Yang X, Yu Y, Xu J, Shu H, Xia A, Liu H, et al. . Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. (2020). 10.1016/S2213-2600(20)30079-5. [Epub ahead of print]. - DOI - PMC - PubMed
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020). 10.1016/S0140-6736(20)30566-3. [Epub ahead of print]. - DOI - PMC - PubMed
    1. Gibbs C, Thalamus J, Kristoffersen DT, Svendsen MV, Holla ØL, Heldal K, et al. . QT prolongation predicts short-term mortality independent of comorbidity. Europace. (201) 21:1254–60. 10.1093/europace/euz058 - DOI - PMC - PubMed
    1. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens Care Med. (2020) 1–3. 10.1007/s00134-020-05991-x. [Epub ahead of print]. - DOI - PMC - PubMed